Region-Specific Changes in Transient Receptor Potential Vanilloid Channel Expression in the Vasopressin Magnocellular System in Hepatic Cirrhosis-Induced Hyponatraemia

Journal of Neuroendocrinology

Volumn 24, Issue 4, 2012, Pages 642-652

  Nedungadi, T P ^a   Carreno F R ^b   Walch, J D ^a,b   Bathina, C S ^a   Cunningham, J T ^a  

^a UNIVERSITY OF NORTH TEXAS   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Bile duct ligation; Laser capture microdissection; TRPV; Vasopressin

Indexed keywords

MESSENGER RNA; OXYTOCIN; VANILLOID RECEPTOR; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 2; VANILLOID RECEPTOR 3; VANILLOID RECEPTOR 4; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HYPONATREMIA; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; MALE; MICRODISSECTION; NONHUMAN; PARAVENTRICULAR THALAMIC NUCLEUS; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPRAOPTIC NUCLEUS; VASOPRESSIN BLOOD LEVEL; VASOPRESSIN RELEASE; WESTERN BLOTTING;

ANIMALS; ARGININE VASOPRESSIN; GENE EXPRESSION REGULATION; HEMATOCRIT; HYPONATREMIA; LASER CAPTURE MICRODISSECTION; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; OSMOLAR CONCENTRATION; OXYTOCIN; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PLASMA; RATS; RATS, SPRAGUE-DAWLEY; SUPRAOPTIC NUCLEUS; TRPV CATION CHANNELS;

EID: 84858849282     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2011.02273.x     Document Type: Article

References (57)

1. Schrier RW. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am J Med 2006; 7(Suppl. 1): S47-S53.
2. Verbalis JG. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab 2003; 17: 471-503.
3. Cardenas A, Arroyo V. Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites. Best Pract Res Clin Endocrinol Metab 2003; 17: 607-622.
4. Martin PY, Schrier RW. Sodium and water retention in heart failure: pathogenesis and treatment. Kidney Int Suppl 1997; 59: S57-S61.
5. Gines P, Berl T, Bernardi M, Bichet DG, Hamon G, Jimenez W, Liard JF, Martin PY, Schrier RW. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998; 28: 851-864.
6. Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol 2005; 95: 8B-13B.
7. Goldsmith SR. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. Am J Cardiol 2005; 95: 14B-23B.
8. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986; 73: 257-267.
9. Packer M, Lee WH, Kessler PD, Medina N, Yushak M, Gottlieb SS. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. J Am Coll Cardiol 1987; 10: 837-844.
10. Papadakis MA, Fraser CL, Arieff AI. Hyponatraemia in patients with cirrhosis. Q J Med 1990; 76: 675-688.
11. Ferguson JW, Therapondos G, Newby DE, Hayes PC. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. Clin Sci (Lond) 2003; 105: 1-8.
12. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112.
13. Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs 2007; 67: 847-858.
14. Ali F, Raufi MA, Washington B, Ghali JK. Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev 2007; 25: 261-279.
15. Gassanov N, Semmo N, Semmo M, Nia AM, Fuhr U, Er F. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH). Eur J Clin Pharmacol 2011; 67: 333-346.
16. Olszewski W, Gluszek J. [Vasopressin antagonists in treatment of hyponatremia]. Pol Arch Med Wewn 2007; 117: 356-362.
17. Wong LL, Verbalis JG. Vasopressin V2 receptor antagonists. Cardiovasc Res 2001; 51: 391-402.
18. Claria J, Jimenez W, Arroyo V, Guarner F, Lopez C, La Villa G, Asbert M, Rivera F, Rodes J. Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats. Gastroenterology 1989; 97: 1294-1299.
19. Claria J, Jimenez W, Arroyo V, La Villa G, Lopez C, Asbert M, Castro A, Gaya J, Rivera F, Rodes J. Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology 1991; 100: 494-501.
20. Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002; 36: 1197-1205.
21. Gines P. Vaptans: a promising therapy in the management of advanced cirrhosis. J Hepatol 2007; 46: 1150-1152.
22. Fernandez-Varo G, Ros J, Cejudo-Martin P, Cano C, Arroyo V, Rivera F, Rodes J, Jimenez W. Effect of the V1a/V2-AVP receptor antagonist, conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J Hepatol 2003; 38: 755-761.
23. Decaux G. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J Lab Clin Med 2001; 138: 18-21.
24. Martin PY, Schrier RW. Pathogenesis of water and sodium retention in cirrhosis. Kidney Int Suppl 1997; 59: S43-S49.
25. Mason WT. Supraoptic neurones of rat hypothalamus are osmosensitive. Nature (London) 1980; 287: 154-157.
26. Oliet SHR, Bourque C. Mechanosensitive channels transduce osmosensitivity in supraoptic neurons. Nature 1993; 364: 341-343.
27. Bourque CW. Central mechanisms of osmosensation and systemic osmoregulation. Nat Rev Neurosci 2008; 9: 519-531.
28. Leng G, Brown CH, Bull PM, Brown D, Scullion S, Currie J, Blackburn-Munro RE, Feng J, Onaka T, Verbalis JG, Russell JA, Ludwig M. Responses of magnocellular neurons to osmotic stimulation involves coactivation of excitatory and inhibitory input: an experimental and theoretical analysis. J Neurosci 2001; 21: 6967-6977.
29. Sudbury JR, Ciura S, Sharif-Naeini R, Bourque CW. Osmotic and thermal control of magnocellular neurosecretory neurons-role of an N-terminal variant of trpv1. Eur J Neurosci 2010; 32: 2022-2030.
30. Liedtke W. Transient receptor potential vanilloid channels functioning in transduction of osmotic stimuli. J Endocrinol 2006; 191: 515-523.
31. Bourque CW, Ciura S, Trudel E, Stachniak TJ, Sharif-Naeini R. Neurophysiological characterization of mammalian osmosensitive neurones. Exp Physiol 2007; 92: 499-505.
32. Sharif-Naeini R, Ciura S, Zhang Z, Bourque CW. Contribution of TRPV channels to osmosensory transduction, thirst, and vasopressin release. Kidney Int 2008; 73: 811-815.
33. Liedtke W, Friedman JM. Abnormal osmotic regulation in trpv4-/- mice. Proc Natl Acad Sci USA 2003; 100: 13698-13703.
34. Ciura S, Liedtke W, Bourque CW. Hypertonicity sensing in organum vasculosum lamina terminalis neurons: a mechanical process involving TRPV1 but not TRPV4. J Neurosci 2011; 31: 14669-14676.
35. Wainwright A, Rutter AR, Seabrook GR, Reilly K, Oliver KR. Discrete expression of TRPV2 within the hypothalamo-neurohypophysial system: implications for regulatory activity within the hypothalamic-pituitary-adrenal axis. J Comp Neurol 2004; 474: 24-42.
36. Hindmarch C, Yao S, Beighton G, Paton J, Murphy D. A comprehensive description of the transcriptome of the hypothalamoneurohypophyseal system in euhydrated and dehydrated rats. Proc Natl Acad Sci USA 2006; 103: 1609-1614.
37. Jonassen TE, Heide AM, Janjua NR, Christensen S. Collecting duct function in liver cirrhotic rats with early sodium retention. Acta Physiol Scand 2002; 175: 237-244.
38. Better OS, Aisenbrey GA, Berl T, Anderson RJ, Handelman WA, Linas SL, Guggenheim SJ, Schrier RW. Role of antidiuretic hormone in impaired urinary dilution associated with chronic bile-duct ligation. Clin Sci (Lond) 1980; 58: 493-500.
39. Brond L, Hadrup N, Salling N, Torp M, Graebe M, Christensen S, Nielsen S, Jonassen TE. Uncoupling of vasopressin signaling in collecting ducts from rats with CBL-induced liver cirrhosis. Am J Physiol Renal Physiol 2004; 287: F806-F815.
40. Breitman DR, Lee SS. Blunted responsiveness of the neuronal activation marker Fos in brainstem cardiovascular nuclei of cirrhotic rats. Hepatology 1997; 26: 1380-1385.
41. Carreno FR, Ji LL, Cunningham JT. Altered central TRPV4 expression and lipid raft association related to inappropriate vasopressin secretion in cirrhotic rats. Am J Physiol Regul Integr Comp Physiol 2009; 296: R454-R466.
42. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. San Diego, CA: Academic Press, 1997.
43. Carreño FR, Walch JD, Dutta M, Nedungadi TP, Cunningham JT. BDNF-TrkB pathway mediates NMDA receptor NR2B subunit phosphorylation in the supraoptic nuclei following progressive dehydration. J Neuroendocrinol 2011; 23: 894-905.
44. Kawasaki M, Ponzio TA, Yue C, Fields RL, Gainer H. Neurotransmitter regulation of c-fos and vasopressin gene expression in the rat supraoptic nucleus. Exp Neurol 2009; 219: 212-222.
45. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101-1108.
46. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta][Delta]CT method. Methods 2001; 25: 402-408.
47. Burbach JP, Luckman SM, Murphy D, Gainer H. Gene regulation in the magnocellular hypothalamo-neurohypophysial system. Physiol Rev 2001; 81: 1197-1267.
48. Meeker RB, Greenwood RS, Hayward JN. Vasopressin mRNA expression in individual magnocellular neuroendocrine cells of the supraoptic and paraventricular nucleus in response to water deprivation. Neuroendocrinology 1991; 54: 236-247.
49. McCabe JT, Kawata M, Sano Y, Pfaff DW, Desharnais RA. Quantitative in situ hybridization to measure single-cell changes in vasopressin and oxytocin mRNA levels after osmotic stimulation. Cell Mol Neurobiol 1990; 10: 59-71.
50. Yue C, Mutsuga N, Sugimura Y, Verbalis J, Gainer H. Differential kinetics of oxytocin and vasopressin heteronuclear RNA expression in the rat supraoptic nucleus in response to chronic salt loading in vivo. J Neuroendocrinol 2008; 20: 227-232.
51. Herman JP, Schäfer MK-H, Watson SJ, Sherman TG. In situ hybridization analysis of arginine vasopressin gene transcription using intron-specific probes. Mol Endocrinol 1991; 5: 1447-1456.
52. Arima H, Kondo K, Kakiya S, Nagasaki H, Yokoi H, Yambe Y, Murase T, Iwasaki Y, Oiso Y. Rapid and sensitive vasopressin heteronuclear RNA responses to changes in plasma osmolality. J Neuroendocrinol 1999; 11: 337-341.
53. Beech DJ, Muraki K, Flemming R. Non-selective cationic channels of smooth muscle and the mammalian homologues of Drosophila TRP. J Physiol 2004; 559: 685-706.
54. Muraki K, Iwata Y, Katanosaka Y, Ito T, Ohya S, Shigekawa M, Imaizumi Y. TRPV2 is a component of osmotically sensitive cation channels in murine aortic myocytes. Circ Res 2003; 93: 829-838.
55. Liedtke W, Choe Y, Marti-Renom MA, Bell AM, Denis CS, Sali A, Hudspeth AJ, Friedman JM, Heller S. Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor. Cell 2000; 103: 525-535.
56. Rutter AR, Ma QP, Leveridge M, Bonnert TP. Heteromerization and colocalization of TrpV1 and TrpV2 in mammalian cell lines and rat dorsal root ganglia. Neuroreport 2005; 16: 1735-1739.
57. Liapi A, Wood JN. Extensive co-localization and heteromultimer formation of the vanilloid receptor-like protein TRPV2 and the capsaicin receptor TRPV1 in the adult rat cerebral cortex. Eur J Neurosci 2005; 22: 825-834.